Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/SCN9A_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/SCN9A_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/SCN9A_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/SCN9A_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0009636 | Colorectum | AD | response to toxic substance | 88/3918 | 262/18723 | 1.12e-06 | 3.72e-05 | 88 |
GO:0009791 | Colorectum | AD | post-embryonic development | 29/3918 | 80/18723 | 1.13e-03 | 1.03e-02 | 29 |
GO:00096361 | Colorectum | SER | response to toxic substance | 71/2897 | 262/18723 | 8.63e-07 | 4.07e-05 | 71 |
GO:00097911 | Colorectum | SER | post-embryonic development | 22/2897 | 80/18723 | 4.12e-03 | 3.36e-02 | 22 |
GO:00096362 | Colorectum | MSS | response to toxic substance | 73/3467 | 262/18723 | 1.26e-04 | 1.94e-03 | 73 |
GO:00097912 | Colorectum | MSS | post-embryonic development | 26/3467 | 80/18723 | 1.91e-03 | 1.66e-02 | 26 |
GO:0035725 | Colorectum | FAP | sodium ion transmembrane transport | 44/2622 | 178/18723 | 9.31e-05 | 1.60e-03 | 44 |
GO:0001508 | Colorectum | FAP | action potential | 34/2622 | 134/18723 | 3.30e-04 | 4.22e-03 | 34 |
GO:0006814 | Colorectum | FAP | sodium ion transport | 54/2622 | 245/18723 | 3.98e-04 | 4.85e-03 | 54 |
GO:00097913 | Colorectum | FAP | post-embryonic development | 23/2622 | 80/18723 | 4.51e-04 | 5.32e-03 | 23 |
GO:00096363 | Colorectum | FAP | response to toxic substance | 53/2622 | 262/18723 | 3.35e-03 | 2.46e-02 | 53 |
GO:00015081 | Colorectum | CRC | action potential | 32/2078 | 134/18723 | 2.02e-05 | 5.90e-04 | 32 |
GO:00357251 | Colorectum | CRC | sodium ion transmembrane transport | 39/2078 | 178/18723 | 2.30e-05 | 6.60e-04 | 39 |
GO:00068141 | Colorectum | CRC | sodium ion transport | 49/2078 | 245/18723 | 3.01e-05 | 7.86e-04 | 49 |
GO:00097914 | Colorectum | CRC | post-embryonic development | 20/2078 | 80/18723 | 3.62e-04 | 5.45e-03 | 20 |
GO:0035637 | Colorectum | CRC | multicellular organismal signaling | 31/2078 | 160/18723 | 1.39e-03 | 1.52e-02 | 31 |
GO:0042391 | Colorectum | CRC | regulation of membrane potential | 67/2078 | 434/18723 | 3.27e-03 | 2.81e-02 | 67 |
GO:00097919 | Esophagus | ESCC | post-embryonic development | 56/8552 | 80/18723 | 9.08e-06 | 8.71e-05 | 56 |
GO:000963620 | Esophagus | ESCC | response to toxic substance | 150/8552 | 262/18723 | 1.00e-04 | 7.12e-04 | 150 |
GO:000979114 | Thyroid | PTC | post-embryonic development | 48/5968 | 80/18723 | 1.99e-07 | 3.56e-06 | 48 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SCN9A | SNV | Missense_Mutation | novel | c.3608N>G | p.Ile1203Ser | p.I1203S | Q15858 | protein_coding | deleterious(0) | probably_damaging(0.968) | TCGA-EO-A3AV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
SCN9A | SNV | Missense_Mutation | rs775461240 | c.583N>A | p.Val195Ile | p.V195I | Q15858 | protein_coding | tolerated(0.09) | probably_damaging(0.962) | TCGA-EO-A3AZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SCN9A | SNV | Missense_Mutation | novel | c.5364C>A | p.Phe1788Leu | p.F1788L | Q15858 | protein_coding | deleterious(0.01) | benign(0.033) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
SCN9A | SNV | Missense_Mutation | novel | c.4712A>G | p.Asp1571Gly | p.D1571G | Q15858 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
SCN9A | SNV | Missense_Mutation | novel | c.3729C>A | p.Phe1243Leu | p.F1243L | Q15858 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
SCN9A | SNV | Missense_Mutation | | c.909T>G | p.Phe303Leu | p.F303L | Q15858 | protein_coding | tolerated(0.11) | benign(0.062) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
SCN9A | SNV | Missense_Mutation | novel | c.476T>G | p.Phe159Cys | p.F159C | Q15858 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
SCN9A | SNV | Missense_Mutation | novel | c.3716A>G | p.Tyr1239Cys | p.Y1239C | Q15858 | protein_coding | deleterious(0.03) | benign(0.062) | TCGA-EO-A3KX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SCN9A | SNV | Missense_Mutation | novel | c.5758N>T | p.Asp1920Tyr | p.D1920Y | Q15858 | protein_coding | deleterious(0.03) | benign(0.348) | TCGA-EY-A1G8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SCN9A | SNV | Missense_Mutation | novel | c.5364N>A | p.Phe1788Leu | p.F1788L | Q15858 | protein_coding | deleterious(0.01) | benign(0.033) | TCGA-EY-A1GD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6335 | SCN9A | DRUGGABLE GENOME, ION CHANNEL | | DWJ-208 | | |
6335 | SCN9A | DRUGGABLE GENOME, ION CHANNEL | blocker | CHEMBL16 | PHENYTOIN | |
6335 | SCN9A | DRUGGABLE GENOME, ION CHANNEL | blocker | 135652722 | TETRODOTOXIN | |
6335 | SCN9A | DRUGGABLE GENOME, ION CHANNEL | | Benzene sulfonamide derivative 11 | | |
6335 | SCN9A | DRUGGABLE GENOME, ION CHANNEL | blocker | CHEMBL1200773 | TOCAINIDE HYDROCHLORIDE | |
6335 | SCN9A | DRUGGABLE GENOME, ION CHANNEL | | Benzene sulfonamide derivative 15 | | |
6335 | SCN9A | DRUGGABLE GENOME, ION CHANNEL | blocker | CHEMBL1200597 | ETIDOCAINE HYDROCHLORIDE | |
6335 | SCN9A | DRUGGABLE GENOME, ION CHANNEL | blocker | CHEMBL2107771 | RALFINAMIDE | |
6335 | SCN9A | DRUGGABLE GENOME, ION CHANNEL | | Aryl carboxamide derivative 4 | | |
6335 | SCN9A | DRUGGABLE GENOME, ION CHANNEL | | RANOLAZINE | RANOLAZINE | |